Aniridia

Aniridia

National Organization for Rare Disorders, Inc.

Important

It is possible that the main title of the report Aniridia is not the name you expected. Please check the synonyms listing to find the alternate name(s) and disorder subdivision(s) covered by this report.

Synonyms

  • Irideremia

Disorder Subdivisions

  • Aniridia Type I
  • AN 1
  • Aniridia Type II
  • AN 2
  • Aniridia Associated with Mental Retardation
  • Wilms Tumor Aniridia Gonadoblastoma Mental Retardation
  • WAGR Syndrome

General Discussion

Aniridia is a rare genetic vision disorder characterized by abnormal development of the eye's iris. The iris is the circular colored membrane in the middle of the eyeball. It is perforated in the center by an opening known as the pupil, which regulates the amount of light that enters the eye. Aniridia is characterized by partial or complete absence of the iris. Various forms of aniridia have been identified. Each can be distinguished by accompanying symptoms.

Symptoms

Aniridia is marked by partial or complete absence of the eye's iris. Vision is preserved in some mild cases of aniridia. The iris fails to develop normally before birth in one or both eyes. At least four types of aniridia are thought to exist. One type is marked by incomplete expression of the disorder. Some people with this type of aniridia may be unaware of the eye problems because pupils appear normal and usually only one eye is affected with thinning of the iris. In a second type of aniridia, iris abnormalities may occur alone, or in combination with other disorders. Accompanying disorders may include cataracts (clouding of the crystalline lens of the eye), glaucoma (gradual loss of vision due to increased pressure inside the eyeball which may be accompanied by varying degrees of pain), or superficial clouding of the cornea (corneal pannus). Rapid involuntary movement of the eyeball (nystagmus), and underdevelopment of the fovea area of the retina (which controls acute vision) may also occur.



A third type of aniridia is associated with mental retardation, and a fourth type occurs in conjunction with Wilms' tumor, genitourinary abnormalities, and possible mental retardation. (For more information on Wilms' Tumor, please choose "Wilm" as your search term in the Rare Disease Database.)

Causes

Until recently, it was thought that two separate genes were responsible for two distinct forms of aniridia. However, a review of the evidence revealed that what was thought to be two forms is actually one and that one gene is responsible. It is known as the PAX6 gene, and it is located on the short arm (p) of chromosome 11 (11p13).



Chromosomes, which are present in the nucleus of human cells, carry the genetic information for each individual. Pairs of human chromosomes are numbered from 1 through 22, and an additional 23rd pair of sex chromosomes which include one X and one Y chromosome in males and two X chromosomes in females. Each chromosome has a short arm designated "p" and a long arm designated "q". Chromosomes are further sub-divided into many bands that are numbered. For example, "chromosome 11p13" refers to band 13 on the short arm of chromosome 11. The numbered bands specify the location of the thousands of genes that are present on each chromosome.



The defect is thought to be inherited as an autosomal dominant trait, although some cases appear to be spontaneous genetic mutations. A second type of Aniridia associated with mental retardation and a third type occurring in conjunction with Wilms' Tumor are also thought to be inherited as autosomal dominant traits.



Genetic diseases are determined by two genes, one received from the father and one from the mother.



Dominant genetic disorders occur when only a single copy of an abnormal gene is necessary for the appearance of the disease. The abnormal gene can be inherited from either parent, or can be the result of a new mutation (gene change) in the affected individual. The risk of passing the abnormal gene from affected parent to offspring is 50% for each pregnancy regardless of the sex of the resulting child.

Affected Populations

All types of Aniridia affect males and females in equal numbers. This disorder is thought to occur in approximately one in 60,000 to 100,000 live births in the United States.

Standard Therapies

Treatment of aniridia is usually directed at improving and preserving vision. Drugs or surgery may be helpful for glaucoma and/or cataracts. Contact lenses may be beneficial in some cases. When a genetic cause cannot be identified, patients should be evaluated for the possibility of the development of Wilms' tumor. (For more information on this disorder, please choose "Wilm" as your search term in the Rare Disease Database.) Services that benefit vision impaired or mentally retarded individuals and their families may be of assistance in some cases. Genetic counseling is recommended. Other treatment is symptomatic and supportive.

Investigational Therapies

The Canadian Foundation for Aniridia Research (CFAR) maintains a close watch on developments involving this disorder. That organization's web site may be reached at

www.aniridia.org.



Information on current clinical trials is posted on the Internet at www.clinicaltrials.gov. All studies receiving U.S. government funding, and some supported by private industry, are posted on this government web site.



For information about clinical trials being conducted at the NIH Clinical Center in Bethesda, MD, contact the NIH Patient Recruitment Office:



Tollfree: (800) 411-1222

TTY: (866) 411-1010

Email: prpl@cc.nih.gov



For information about clinical trials sponsored by private sources, contact:

www.centerwatch.com

References

TEXTBOOKS

Lauderdale JD. Aniridia. In: NORD Guide to Rare Disorders. Lippincott Williams & Wilkins. Philadelphia, PA. 2003:640.



Kanski JJ., ed. Clinical Ophthalmology, 4th ed. Woburn, MA: Butterworth-Heinemann; 1999:240-42.



REVIEW ARTICLES

Prosser J, et al. PAX6 mutations reviewed. Hum Mutat. 1998;11:93-108.



Dahl E, et al. Pax genes and organogenesis. Bioessays. 1997;19:755-65.



Gehring WJ. The master control gene for morphogenesis and evolution of the eye. Genes Cells. 1996;1:11-15.



JOURNAL ARTICLES

Laghmari M, et al. Bilateral congenital aniridia: 5 case reports. J Fr Ophthalmol. 2004;27:385-91.



Zumkeller W, Orth U, Gal A. Three novel PAX6 mutations in patients with aniridia. Mol Pathol. 2003;56:180-3.



Churchill AJ, et al. Prenatal diagnosis of aniridia. Ophthalmology. 2000;107:1153-56.



Chao LY, et al. Mutation in the PAX6 gene in twenty patients with aniridia. Hum Mutat. 2000;15:332-39.



Hartmann RW Jr, et al. Picture of the month. Congenital aniridia. Arch Pediatr Adolesc Med. 2000;154:525-26.



Tanzer DJ, et al. Black iris-diaphragm intraocular lens for aniridia and aphakia. J Cataract Refract Surg. 1999;25:1548-51.



Osher RH, et al. Cataract surgery combined with implantation of an artifical iris. J Cataract Refract Surg. 1999;25:1540-47.



Chen TC, et al. Goniosurgery for prevention of aniridic glaucoma. Arch Ophthalmol. 1999;117:1144-48.



FROM THE INTERNET

McKusick VA, ed. Online Mendelian Inheritance in Man (OMIM). Baltimore. MD: The Johns Hopkins University; Entry No:106200; Last Edit: 6/8/1994; Entry No: 106210; Last Update: 5/2/2000.

Resources

Lighthouse International

111 E 59th St

New York, NY 10022-1202

Tel: (800)829-0500

Email: info@lighthouse.org

Internet: http://www.lighthouse.org



The Arc

1825 K Street NW, Suite 1200

Washington, DC 20006

Tel: (202)534-3700

Fax: (202)534-3731

Tel: (800)433-5255

TDD: (817)277-0553

Email: info@thearc.org

Internet: http://www.thearc.org



National Association for Parents of Children with Visual Impairments (NAPVI)

P.O. Box 317

Watertown, MA 02272-0317

Tel: (617)972-7441

Fax: (617)972-7444

Tel: (800)562-6265

Email: napvi@perkins.org

Internet: http://www.napvi.org



NIH/National Eye Institute

31 Center Dr

MSC 2510

Bethesda, MD 20892-2510

United States

Tel: (301)496-5248

Fax: (301)402-1065

Email: 2020@nei.nih.gov

Internet: http://www.nei.nih.gov/



Aniridia Network UK

22 Cornish House

Adelaide Lane

Sheffield, S3 8BJ

United Kingdom

Tel: 4407792867949

Email: info@aniridia.org.uk

Internet: http://www.aniridia.org.uk



Genetic and Rare Diseases (GARD) Information Center

PO Box 8126

Gaithersburg, MD 20898-8126

Tel: (301)251-4925

Fax: (301)251-4911

Tel: (888)205-2311

TDD: (888)205-3223

Internet: http://rarediseases.info.nih.gov/GARD/



Cornea Research Foundation of America

9002 North Meridian Street

Ste. 212

Indianapolis, IN 46260

Tel: (317)844-5610

Fax: (317)814-2806

Tel: (800)317-3937

Email: elainevoci@cornea.org

Internet: http://www.cornea.org



For a Complete Report

This is an abstract of a report from the National Organization for Rare Disorders, Inc.® (NORD). Cigna members can access the complete report by logging into myCigna.com. For non-Cigna members, a copy of the complete report can be obtained for a small fee by visiting the NORD website. The complete report contains additional information including symptoms, causes, affected population, related disorders, standard and investigational treatments (if available), and references from medical literature. For a full-text version of this topic, see http://www.rarediseases.org/search/rdblist.html.

This information does not replace the advice of a doctor. Healthwise, Incorporated disclaims any warranty or liability for your use of this information. Your use of this information means that you agree to the Terms of Use . How this information was developed to help you make better health decisions.

Healthwise, Healthwise for every health decision, and the Healthwise logo are trademarks of Healthwise, Incorporated.